Detailed Information on Publication Record
2014
Chemoterapie a její místo v současné léčbě pokročilého hormonálně dependentního karcinomu prsu
BRANČÍKOVÁ, Dagmar, Eva JANDÁKOVÁ, Markéta PROTIVÁNKOVÁ, Karel DVOŘÁK, Luboš MINÁŘ et. al.Basic information
Original name
Chemoterapie a její místo v současné léčbě pokročilého hormonálně dependentního karcinomu prsu
Name in Czech
Chemoterapie a její místo v současné léčbě pokročilého hormonálně dependentního karcinomu prsu
Name (in English)
Chemotherapy and its role in contemporary treatment of advanced hormone-dependent breast cancer
Authors
BRANČÍKOVÁ, Dagmar (203 Czech Republic, guarantor), Eva JANDÁKOVÁ (203 Czech Republic), Markéta PROTIVÁNKOVÁ (203 Czech Republic, belonging to the institution), Karel DVOŘÁK (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), Otakar BEDNAŘÍK (203 Czech Republic, belonging to the institution), Petr SZTURZ (203 Czech Republic, belonging to the institution) and Zdeněk MECHL (203 Czech Republic)
Edition
Farmakoterapie, Praha, Farmakon Press, 2014, 1801-1209
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/14:00076356
Organization unit
Faculty of Medicine
Keywords in English
breast cancer; chemotherapy; neoadjuvance; luminal
Tags
Změněno: 17/9/2014 14:53, Soňa Böhmová
V originále
Individualizovaná léčba karcinomu prsu je v onkologii významným krokem vpřed. Hlavními, již roky prověřenými prediktory jsou receptory pro estrogen a progesteron, HER2/neu, a s postupně se zdokonalujícími metodami molekulární biologie je léčba stratifikována dle „intrinsic tumor" fenotypu.
In English
The role of neoadjuvant therapy for locally advanced breast cancer is undisputed and is due to the treatment algorithm an appropriate object of clinical studies. Even though the patient of luminal hormone treatment benefit, are not information about the benefits of chemotherapy. At the luminal tumors B is proved a unique profit from treatment antracykliny and taxan, especially at the luminal HER pozitive type. The introduction of Intrinsic subtype into the treatment of advanced tumor subtype of breast cancer has a unique output. For subtypes of luminal A axillae nodes pozitive was profit from chemotherapy proved, in the case of luminal B is profit unique, the most benefits for a group of Luminal HER positive tumors, where in the case of neoadjuvance wait until 50% of pathological complete remission (pCR) and overall survival is better than luminal B without the positivity of the HER. The best experiences are in neoadjuvant with the antracyklins and taxans , in the case of luminal A does not benefit from antracyklins unique, and you can choose nonantracyklin mode. At the luminal HER group (Luminal B HER+) shows a better answer a combination of inhibitors of the HER receptor (pertuzumab), however the results we need to definitive some time to wait. At the luminal tumors HER 2 neu positive Luminal A pCR does not correlate with the overall survival.